Literature DB >> 23333664

Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage.

Toshio Watanabe1, Tetsuya Tanigawa, Yuji Nadatani, Yasuaki Nagami, Satoshi Sugimori, Hirotoshi Okazaki, Hirokazu Yamagami, Kenji Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara, Tatsuya Koike, Tetsuo Arakawa.   

Abstract

BACKGROUND: Few studies have assessed the risk factors associated with nonsteroidal anti-inflammatory drugs (NSAIDs)-induced small intestinal damage. AIMS: To evaluate the risk factors for NSAID-induced enteropathy in patients with rheumatoid arthritis.
METHODS: A cross-sectional study using capsule endoscopy was conducted. A total of 113 patients who took NSAIDs for over 3 months underwent capsule endoscopies. Endoscopic findings were scored as (0) normal, (1) red spots, (2) 1-4 erosions, (3) >4 erosions, or (4) large erosions/ulcers. Initial scores were grouped into 3 categories: No damage (0-1), mild damage (2), and severe damage (3-4), and the potential risk factors for damage development were assessed.
RESULTS: Five patients were excluded because of incomplete visualization of the entire small intestine. Fifty-two (47.2%) and 27 (25%) patients had no damage and mild damage, respectively, while the remaining 30 patients (27.8%) had severe damage and significantly decreased hemoglobin levels. In a multivariate logistic regression analysis, ages of 65 years or more (odds ratio [OR], 4.16; 95% confidence interval [CI], 1.51-11.47), proton pump inhibitor usage (OR, 5.22; 95% CI, 1.36-20.11), and histamine H2 receptor antagonist usage (OR, 3.95; 95% CI, 1.28-12.25) were independent risk factors for severe damage.
CONCLUSIONS: Elderly patients and acid suppressant users are more likely to develop severe NSAID-induced enteropathy.
Copyright © 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23333664     DOI: 10.1016/j.dld.2012.12.005

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  29 in total

1.  Prevention of NSAID-Enteropathy: A Soluble Problem?

Authors:  John L Wallace
Journal:  Dig Dis Sci       Date:  2016-01       Impact factor: 3.199

Review 2.  Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury.

Authors:  John L Wallace; Angela Ianaro; Gilberto de Nucci
Journal:  Dig Dis Sci       Date:  2017-07-21       Impact factor: 3.199

Review 3.  NSAID enteropathy and bacteria: a complicated relationship.

Authors:  Stephanie D Syer; Rory W Blackler; Rebeca Martin; Giada de Palma; Laura Rossi; Elena Verdu; Premek Bercik; Michael G Surette; Anne Aucouturier; Philippe Langella; John L Wallace
Journal:  J Gastroenterol       Date:  2015-01-10       Impact factor: 7.527

Review 4.  Microscopic colitis-microbiome, barrier function and associated diseases.

Authors:  Saskia van Hemert; Karolina Skonieczna-Żydecka; Igor Loniewski; Piotr Szredzki; Wojciech Marlicz
Journal:  Ann Transl Med       Date:  2018-02

Review 5.  Polypharmacy of osteoarthritis: the perfect intestinal storm.

Authors:  John L Wallace
Journal:  Dig Dis Sci       Date:  2013-07-25       Impact factor: 3.199

6.  Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota.

Authors:  Rory W Blackler; Jean-Paul Motta; Anna Manko; Matthew Workentine; Premysl Bercik; Michael G Surette; John L Wallace
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

7.  Gut Microbiome and Response to Cardiovascular Drugs.

Authors:  Sony Tuteja; Jane F Ferguson
Journal:  Circ Genom Precis Med       Date:  2019-08-28

Review 8.  Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence.

Authors:  Jacek Budzyński; Marek Koziński; Maria Kłopocka; Julia Maria Kubica; Jacek Kubica
Journal:  Clin Res Cardiol       Date:  2014-05-10       Impact factor: 5.460

9.  Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy?

Authors:  Hiroki Endo; Takayuki Kato; Eiji Sakai; Leo Taniguchi; Jun Arimoto; Harunobu Kawamura; Takuma Higurashi; Hidenori Ohkubo; Takashi Nonaka; Masataka Taguri; Masahiko Inamori; Takeharu Yamanaka; Takashi Sakaguchi; Yasuo Hata; Hajime Nagase; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2016-04-19       Impact factor: 7.527

Review 10.  Eicosanoids in the gastrointestinal tract.

Authors:  John L Wallace
Journal:  Br J Pharmacol       Date:  2018-04-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.